Leerink Maintains Market Perform Rating on Amgen, Raises Target to $464
Leerink Partners maintained its Market Perform rating on Amgen and raised its price target to $464 per share from $395.
Leerink Partners maintained its Market Perform rating on Amgen and raised its price target to $464 per share from $395.